Tonix Pharma rises on positive data from preclinical study of colorectal cancer therapy

Mar. 07, 2023 9:25 AM ETTonix Pharmaceuticals Holding Corp. (TNXP)By: Dania Nadeem, SA News Editor

Gastroenterologist doctor, intestine specialist. Aesthetic handdrawn highlighted illustration of human intestine. Dark grey background, studio photo and collage.

mi-viri

  • Tonix Pharma (NASDAQ:TNXP) is trading 5% higher premarket after its therapy, Murine TNX-1700, showed anti-tumor activity of PD-1 blockade in mouse models of colorectal cancer.
  • The therapy, TNX-1700, is currently in development as monotherapy and in combination with Anti-PD-1 checkpoint inhibitor therapy for colorectal and gastric cancers.
  • The therapy targets myeloid-derived suppressor cells (MDSCs) which interfere with the immune response to cancer.
  • The treatment leads to the activation of cancer-killing CD8+ T cells.
  • Press Release

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.